The ability to predict the pathology underlying different neurodegenerative syndromes is of critical importance owing to the advent of molecule-specific therapies.
P rimary progressive aphasia (PPA) is a clinically and pathologically heterogeneous condition in which language impairment is the predominant cause of functional impairment during the initial phases of disease.
1 In 2011, an international consortium of investigators established a classification scheme for the 3 most common variants: the semantic (svPPA), nonfluent/agrammatic (nfvPPA), and logopenic (lvPPA) variants of PPA. 2 Classification may occur at 1 of 3 levels: clinical, imaging-supported, or definite pathologic diagnosis. These guidelines reflected the accumulated knowledge of the patterns of speech and language dysfunction, brain atrophy, and underlying pathology typically associated with each clinical variant and represent a collective effort to increase comparability between studies and eventually improve the ability to predict the underlying pathology. The ability to detect fibrillar amyloid-β plaque depositions using carbon 11-labeled Pittsburgh Compound-B ( 11 C-PIB) 3 or fluorinated amyloid positron emission tomography (PET) tracers 4 allows in-vivo identification of cases due to putative Alzheimer disease. A few studies have reported amyloid imaging and pathologic results in PPA. [5] [6] [7] [8] Taken together, these reports suggest that svPPA and nfvPPA are generally caused by frontotemporal lobar degeneration (FTLD), 9 mainly tau (including Pick disease, corticobasal degeneration, progressive supranuclear palsy) and TAR-DNA binding protein 43 (TDP-43) proteinopathies, while lvPPA is mostly caused by Alzheimer disease. However, the prevalence of FTLD and Alzheimer disease pathologic findings or biomarkers in each variant has been inconsistent across the literature (svPPA, 0%-16% Alzheimer disease; nfvPPA, 13%-31%; lvPPA, 54%-92%). [5] [6] [7] [8] [10] [11] [12] [13] [14] This may be caused by the fact that most of these studies are retrospective and may not have had adequate records or appropriate test batteries to apply the current criteria. Therefore, prospective validation with biomarker and autopsy data remains scarce and highly necessary. We studied amyloid brain imaging in a large cohort of patients with prospectively diagnosed PPA to test the hypothesis that classification according to the current criteria in wellcharacterized patients with language and magnetic resonance imaging (MRI) evaluations will result in groups with largely homogeneous biomarker features. A second objective was to analyze amyloid "discordant" (amyloid positive svPPA and nfvPPA and amyloid negative lvPPA) and mixed cases (PPAm) in search of characteristics that may aid in their identification.
Methods

Participant Selection and Characterization
We recruited participants that presented prospectively to the University of California San Francisco (UCSF) Memory and Aging Center between January 2002 and December 2015 as part of an ongoing PPA research project. We included patients that met the following criteria: clinical diagnosis of PPA; availability of complete speech, language, and cognitive test results; MRI performed within 6 months of the cognitive evaluation; and PET 11 C-PiB or florbetapir F 18 brain scan results. As part of the research evaluation, all participants underwent a history and physical examination by a neurologist, a structured caregiver interview by a nurse, a battery of neuropsychological tests, multimodal brain imaging scans, as well as an extensive battery of language tests. After initial evaluation, a syndromic diagnosis was reached by consensus between the multidisciplinary evaluation team. Initial diagnosis was based on clinical judgment after considering all available neurologic, cognitive, language, and structural MRI data. Amyloid imaging results were not available for any participant at the time of initial diagnosis. Since 2002, the UCSF Memory and Aging Center PPA research project has classified patients with PPA into svPPA, nfvPPA, and lvPPA using the same core clinical evaluation presented in this article. The features used for classification have remained largely analogous since they were first described in 2004
15
; however, they have been refined and operationalized by senior investigators in the field as described in 2008 and 2011. 2,16 The tripartite framework of the classification system and the nature of the delineated patient groups have not changed during the evolution of the criteria (see eAppendix 1 in the Supplement). Furthermore, each case that presented before 2011 was reviewed retrospectively to determine if their diagnosis would change with application of current criteria, and none warranted change. We report the prospective PPA clinical variant diagnoses made by consensus at presentation between 2002 and 2015. When it was not possible to identify a predominant area of language impairment or more than 1 area was impaired (eg, motor speech, repetition difficulties), a diagnosis of PPAm was made. One hundred and nine patients were referred to the UCSF Memory and Aging Center for evaluation of language symptoms and underwent amyloid imaging between 2002 and 2015. Of these, 3 patients were excluded because of inability to complete the language evaluation owing to advanced severity of disease, 5 for absence of significant aphasia, and 12 for presenting with significant initial symptoms outside of the language domain and consequently not meeting root PPA criteria (eTable in the Supplement). This left a cohort of 89 patients
Key Points
Question What are the rates and significance of amyloid imaging positivity in a large cohort of patients with the main variants of primary progressive aphasia (PPA) prospectively diagnosed according to 2011 consensus criteria?
Findings In this longitudinal case-series study, 24 of 28 patients with semantic variant PPA (86%) and 28 of 31 patients with nonfluent/agrammatic variant PPA (90%) had negative amyloid positron emission tomography scans, whereas 25 of 26 patients with logopenic variant (96%) and 3 of 4 patients with PPA with mixed phenotype (75%) had positive scans. The amyloid positive semantic PPA and nonfluent/agrammatic PPA cases with available autopsy data (2 of 4 and 2 of 3, respectively) all had a primary frontotemporal lobar degeneration and secondary Alzheimer disease pathologic diagnoses.
Meaning Primary progressive aphasia variant diagnosis according to the current classification scheme is highly predictive of Alzheimer disease biomarker status; biomarker positivity for Alzheimer disease may be more predictive of mixed pathology rather than primary Alzheimer disease. 
Structural Magnetic Resonance Imaging
All patients and control individuals underwent whole-brain structural MRI using a 1.5T (Siemens Healthcare), 15,24 3T
(Siemens Healthcare), 25 or 4T (Bruker Corporation and Siemens Healthcare) 26 scanner as previously described. We used voxelbased morphometry to study gray-matter atrophy patterns of svPPA (n = 24), nfvPPA (n = 28), and lvPPA (n = 25) groups (only including cases with typical amyloid imaging status) as well as each individual case with discordant amyloid imaging status and each PPAm case (eAppendix 2 in the Supplement).
Positron Emission Tomography
Carbon 11-labeled Pittsburgh Compound-B (n = 99) and florbetapir F 18 (n = 10) PET were performed at Lawrence Berkeley National Laboratory as previously described. 27 Native space standardized uptake value ratios (SUVRs) were created for 11 C-PIB scans only by normalizing mean images (at 50-to 70-minutes postinjection) by mean activity in cerebellum gray matter. 
Results
Demographic and Genetic Data
Comparison of demographic characteristics ( 
Cognitive and MRI Comparisons
As a group, patients with nfvPPA had less impairment on MiniMental State Examination and Clinical Dementia Rating Sum of Boxes (Table 1 ). All variants showed relatively preserved figure copying. Patients with svPPA showed preserved working memory and executive functions but more behavioral impairment than both nfvPPA and lvPPA groups. Patients with lvPPA performed worse on the number location and calculation tests than patients with svPPA and nfvPPA, respectively. Both patients with lvPPA and those with svPPA scored worse than patients with nfvPPA on free recall of a list of learned words, but only patients with lvPPA scored worse on recall of the Benson figure.
Language testing revealed expected group differences based on the criteria for PPA subtyping (Table 1) . Patients with svPPA scored significantly worse than both nfvPPA and lvPPA groups on tests of verbal semantic knowledge and semantic association of pictures using the Pyramids and Palm Trees Test. Greater presence of apraxia of speech, dysarthria, and
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Age at symptom onset, y 59 (7) Table 2 NA TDP-C +AD TDP-C +AD NA See Table 2 CBD +AD +TDP-A PiD + AD NA See Table 2 decreased fluency scores differentiated patients with nfvPPA from both lvPPA and svPPA groups. Frank agrammatism in speech or writing was detected in 25 of 31 patients with nfvPPA (80.6%). Patients with lvPPA scored significantly worse than those in the svPPA group on sentence repetition. Voxel-based morphometry analysis of PPA subgroups vs control groups also revealed the expected patterns of atrophy associated with each variant (Figure 1) , bilateral predominantly left anterior temporal lobe in patients with svPPA, left posterior frontal lobe in patients with nfvPPA, and left midposterior temporal and inferior parietal lobes in patients with lvPPA.
Amyloid Imaging and Autopsy Results
Mean (SD) time between first-diagnosis PET and PETautopsy was 244 (337) and 1641 (926) days, respectively. Overall prevalence of amyloid PET positivity in the PPA cohort was 35 of 89 (39.3%). Twenty-four of 28 patients with svPPA (85.7%) and 28 of 31 patients with nfvPPA (90.3%) had negative amyloid PET scans, whereas 25 of 26 patients with lvPPA were amyloid positive (96.1%). For comparison, the rates of amyloid PETpositivity in patients with svPPA and nfvPPA were similar to those reported in cognitively normal individuals at a similar age (15%-20% in individuals aged 60-65 years 32 ), whereas the rate in lvPPA was much higher than expected for age. Of the 4 patients with PPAm, 3 were amyloid positive and 1 was negative. Patients with lvPPA had significantly greater 11 C-PiB SUVR than those with nfvPPA and svPPA ( Figure 2 and Table 1 ). Although they were considered to have positive results for the purposes of this study, 1 patient with svPPA and another with nfvPPA received "equivocally positive" amyloid PET reads. These patients showed evidence of focal tracer uptake in regions of early amyloid positivity (eg, precuneus/posterior cingulate cortex, dorsomedial and dorsolateral prefrontal cortex, in contrast to the widespread binding patterns across large regions of association cortex that are typical in advanced Alzheimer disease 27 ). Accordingly, both cases had global SUVRs consistent with early positivity (1.23 and 1.36, respectively) but lower than the conservative threshold used in our group to "rule-in" Alzheimer disease-like levels of binding (global SUVR, ≥1.40).
Autopsy diagnoses were available for 20 patients ( Table 2) . Overall, patients with positive amyloid scans all had intermediate to high Alzheimer disease neuropathological changes. When the PPA phenotype was lvPPA, positive amyloid PET was associated with primary Alzheimer disease, whereas when the PPA phenotype was nfvPPA or svPPA, the primary causative neuropathology was FTLD, with Alzheimer disease present as a contributing copathology. Conversely, all patients with negative amyloid imaging results had absent to low Alzheimer disease neuropathological changes, with FTLD as the primary causative neuropathology. 
PPA With Discordant Amyloid Status
Amyloid Negative lvPPA (Patient H)
Patient H had amyloid negative lvPPA and an SUVR of 1.3 and autopsy data was not available. Her prominent impairment was in sentence repetition but also had worse single word comprehension than the amyloid positive group. Voxel-based morphometry revealed a frontotemporal pattern of atrophy.
PPA Mixed
Three of 4 patients with PPAm (patients W, X, and Y) were amyloid positive and had SUVR greater than 2.2 ( Table 1 ). The only patient that had an autopsy (patient Z) had FTLD-Pick disease. All patients showed word finding difficulties. At presentation, patients W and X showed impaired motor speech Scatterplot depicting positron emission tomography carbon 11-labeled Pittsburgh Compound-B ( 11 C-PIB) standardized uptake value ratios (SUVR) across primary progressive aphasia (PPA) variants (A).
11 C-PIB axial slices of a representative patient with semantic PPA (svPPA) (B), nonfluent/agrammatic PPA (nfvPPA) (C), and logopenic PPA (lvPPA) (D). L indicates left; R, right.
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Rates of Amyloid Imaging Positivity in Patients With Primary Progressive Aphasia (apraxia of speech and dysarthria), sentence repetition, and grammar comprehension. Patient Y presented with impaired semantics, sentence repetition, and grammar comprehension. Patient Z showed impaired grammar, semantics, sentence repetition, and grammar comprehension. Consistent with their clinical presentation, these patients did not show the typical patterns of atrophy seen in the 3 main variants ( Figure 3 ).
Discussion
We report amyloid brain imaging and cognitive and structural MRI results in the largest PPA cohort, to our knowledge, prospectively diagnosed using current criteria. Classification according to PPA variant was associated with Alzheimer disease biomarker status, with the logopenic variant being associated with 11 C-PIB deposition in more than 95% of the patients with sporadic PPA. Furthermore, we found that most cases with typical svPPA and nfvPPA and an unexpected positive amyloid scan had mixed FTLD and Alzheimer disease pathology. These results suggest that typical clinical and MRI findings in svPPA and nfvPPA variants are associated with the presence of FTLD pathology, even in the face of discordant molecular Alzheimer disease biomarker results.
Association of PPA Variant Classification According to Current Consensus Criteria With Amyloid Imaging Biomarker Status
Four of 28 patients with svPPA (15%) and 3 of 31 patients with nfvPPA (10%) had a positive amyloid PET scan. These rates are similar to, if not slightly lower than, the reported prevalence of amyloid positivity in normal individuals at a similar age (15%-20%). 32 These results are in line with other prospective studies, reporting amyloid positivity in 1 of 9 patients with svPPA and 2 of 8 patients with nfvPPA, 8 0 of 3 patients with svPPA and 0 of 11 patients with nfvPPA, 10 and 3 of 9 patients with svPPA and 7 of 52 patients with nfvPPA 34 (the last study included patients labeled as having primary progressive apraxia of speech). Clinicopathologic studies retrospectively applying current criteria also report increased homogeneity of pathologic diagnoses within each PPA variant; however, the prevalence of an Alzheimer disease pathologic diagnosis is more heterogenous, particularly in lvPPA and nfvPPA (0%-16% svPPA, 13%-31% nfvPPA, and 54%-77% lvPPA). [5] [6] [7] 35 Although well-studied cases of nfvPPA and svPPA with Alzheimer disease pathology have been reported, 36,37 it is possible that the higher percentage of Alzheimer disease in these studies is due in part to the difficulty of retrospectively assessing key diagnostic features such as apraxia of speech, agrammatism, repetition, and semantic impairment. Even today, these key features are evaluated with different instruments across centers and represent a significant hurdle for comparison and generalization of results. Furthermore, all of the amyloid discordant cases with available autopsy data (two svPPA and two nfvPPA) in our study had primary FTLD and secondary Alzheimer's disease pathological diagnoses suggesting that a substantial proportion of amyloid positive svPPA and nfvPPA patients may have a primary FTLD pathologic diagnosis with amyloid as a contributing or incidental pathology. Our finding of only 1 amyloid negative out of 26 patients with lvPPA (96% amyloid positive) is also in line with the rates of amyloid positivity (80%-100%) reported in other prospective PPA cohort studies. 8, 10, 11 Despite the general association of lvPPA with Alzheimer disease, this study and others have reported cases of patients prospectively 8, [11] [12] [13] and retrospectively diagnosed as having lvPPA [5] [6] [7] 14 without Alzheimer disease biomarkers or pathology. The studies reporting retrospective diagnoses all report higher rates of non-Alzheimer disease pathology in lvPPA than the ones reporting prospective diagnoses possibly due to the absence of targeted neuropsychological evaluations that have been implemented more recently. The reasons for discrepancies in the rates of amyloid-negative lvPPA are unknown but probably reflect real differences in patient cohorts (such as absence of mutation carriers in our cohort) as well as variability in the application of diagnostic criteria across centers.
PPA With Discordant Amyloid Status
We did not find any demographic, genetic, cognitive, or neuroimaging features that reliably distinguished amyloid positive svPPA or nfvPPA from their primarily amyloid-negative counterparts. Carrying an apolipoprotein E ε4 allele was a risk factor for amyloid positivity even within just svPPA and nfvPPA (odds ratio, 5.6; 95% CI, 1.1-29.1; P = .04). No genetic mutations were found in any of these cases. All 4 amyloid-positive patients with svPPA showed the same language and atrophy profiles as the amyloid-typical group concordant with the available autopsy data and suggest FTLD may be the primary pathologic diagnosis in all 4 patients. Two patients showed highly impaired set shifting in the Modified Trail Making Test, which is unusual for typical svPPA and may reflect an Alzheimer disease contribution to the clinical picture. 38 All amyloidpositive patients with nfvPPA also showed the typical language profile and a common area of atrophy in the left posterior frontal lobe, although each case presented different areas of accompanying atrophy perhaps reflecting the heterogeneous pathologic diagnoses that are known to be associated with nfvPPA. The amyloid negative lvPPA case in our cohort showed more semantic impairment, and her pattern of left temporal atrophy was more anterior and left asymmetric than the amyloid positive lvPPA group. Recent studies have also reported a trend toward worse semantics 13 and greater left asymmet- 
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Rates of Amyloid Imaging Positivity in Patients With Primary Progressive Aphasia ric anterior temporal atrophy and/or hypometabolism 11, 12 in amyloid-negative lvPPA. According to current genetic and pathologic data, most amyloid negative lvPPA cases are associated with an autosomal dominant granulin mutation 11, 39 or sporadic TDP-43-A pathology.
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Diagnosis According to Current PPA Consensus Criteria Classified the Majority of Patients Who Met Root PPA Criteria
Similar to other recent studies, [6] [7] [8] we identified the initial predominantly impaired language domain and classify almost all (85 of 89 [95.5%]) patients that met root PPA criteria. However, some studies report inability to classify a higher proportion of patients, especially when attempting data-driven vs clinical classification methods. 40, 41 The 2 main issues described in previous reports are that a significant number of patients present with both agrammatism and sentence repetition impairment, thus meeting criteria for both nfvPPA and lvPPA, while other patients present only with anomia and thus do not meet any criteria. 5, 34 Despite the existence of unclear cases that required discussion, in our experience and that of others, application of current criteria and targeted speech and language assessments using clinical judgment to identify the predominantly impaired and relatively spared language domains can resolve many of these cases. Furthermore, visual inspection of MRI scans were always used when available to make an imaging-supported diagnosis as defined in the consensus criteria. 2 It is also important to note that the low number of mixed cases in our cohort might be related to the absence of progranulin mutation carriers, who have been shown to present with a logopenic-like mixed PPA syndrome. 39 A possible factor in the absence of patients presenting only anomia in our cohort could be that the aphasia tended to be further evolved before referral to our specialty center. All 4 patients with PPAm in our cohort presented a mix of core features and atrophy typical of more than 1 variant, which were thought to contribute significantly to the clinical picture. Even before knowing the result of the amyloid imaging, Alzheimer disease was the predicted pathology in both patients with mixed phonological and motor speech impairment due to the relative predominance of phonologic impairment, posterior vs frontal atrophy, and presence of impaired memory neuropsychological scores. No patients presented with another previously described PPAm phenotype of equally impaired grammatical production and verbal semantics.
42 Further studies including larger numbers of mixed cases are needed to determine if these present with consistent clinicalpathologic associations.
Limitations
The main limitations of this study stem from the sample size and possible referral bias. Primary progressive aphasia is a rare disorder, and despite the relatively large size and extensive characterization (clinical, cognitive, and multimodal neuroimaging) of our cohort, the sample size is too small to establish firm conclusions. In particular, our findings with respect to the amyloid discordant and mixed PPA cases warrant further study. Another issue that could limit generalization of our results is referral bias. For example, a possible factor in the absence of patients presenting only anomia in our cohort could be that the aphasia tended to be further evolved prior to referral to our specialty center. Referral bias could also be a factor in the small numbers of mixed cases and patients with genetic mutations in our cohort compared to other centers that report a higher proportion of patients with these characteristics.
Conclusions
Primary progressive aphasia variant imaging-confirmed diagnosis according to 2011 consensus classification was associated with Alzheimer disease biomarker status. Furthermore, our results emphasize that positive amyloid biomarker status does not rule out the possibility of a primary FTLD pathologic process driving the clinical syndrome.
eAppendix 1. Evolution of Primary Progressive Aphasia Clinical Variant Diagnostic Criteria Used at the UCSF Memory and Aging Center
One of the main objectives of this study is to determine if prospective diagnosis using a tripartite classification system will result in patient groups with homogeneous biomarker profiles and therefore any changes in the diagnostic criteria could potentially affect the results if these changes distorted the nature of the identified patient groups. We addressed this concern by retrospectively reviewing each case that presented before the current criteria were published in 2011 and confirming that none of the diagnoses warranted change. In the following section we will review the evolution of the criteria as described in the UCSF Memory and Aging Center publications cited below and show that the criteria identify the same patient groups. The UCSF MAC primary progressive aphasia longitudinal study has classified patients with PPA into semantic, non-fluent/agrammatic, and logopenic variants since its start in 2002 using the same core clinical evaluation presented in this manuscript. The features used for classification have remained largely analogous since they were first described in 2004 (Gorno-Tempini et al., 2004) , however they have been refined and operationalized by senior investigators in the field as described in 2008 and 2011 (Rabinovici et al., 2008; .
The 2004 publication stated a diagnosis of progressive non-fluent aphasia (PNFA) required at least two of the following:
(1) motor speech deficits; (2) agrammatism in language production; (3) spared single-word comprehension and impaired comprehension of complex syntactic structures. The criteria described in 2008 resulted from a PPA workshop attended by senior investigators in the field. A diagnosis of PNFA required: (1) motor speech deficits; (2) agrammatism in language production; (3) deficit in comprehension of complex sentences; and (4) spared single-word comprehension and object knowledge. According to current consensus diagnostic criteria published in 2011, a diagnosis of nfvPPA requires at least one of the following core features: (1) Agrammatism in language production; (2) Effortful, halting speech with inconsistent speech sound errors and distortions (apraxia of speech) and at least 2 of 3 of the following features: (1) Impaired comprehension of syntactically complex sentences; (2) Spared single-word comprehension; (3) Spared object knowledge.
The criteria for semantic dementia or the semantic variant in 2004 required at least three of the following: (1) no grammatical errors and normal language output (circumlocutions and usage of nonspecific words were accepted); (2) scores below two standard deviations from the control mean in the 60-item Boston naming test (BNT); (3) scores below two standard deviations from the control mean in the Pyramid and Palm Trees (PPT) test; and (4) normal syntactic comprehension; In 2008 the following were required (1) fluent and grammatically correct language output, (2) semantic memory deficit, (3) confrontation naming deficit, and (4) surface dyslexia. The 2011 criteria require, both core features: (1) Impaired confrontation naming; (2) Impaired single-word comprehension; and at least 3 of the following features: (1) Impaired object knowledge, particularly for low frequency or low-familiarity items; (2) Surface dyslexia or dysgraphia; (3) Spared repetition (4) Spared speech production (grammar and motor speech).
The 2004 publication which first described the logopenic variant did not present operationalized criteria, instead these patients were characterized as not showing "a pattern of speech and language deficit compatible with NFPA or SD… their language output was slow in rate, grammatically simple but correct, and halted by frequent word-finding pauses… Agrammatism in production and articulation deficits were not typical of LPA patients. Single word comprehension, recognition of nonnamed items, and performance on the semantic association test were relatively spared, whereas syntactic comprehension was markedly impaired. The deficit was not limited to the most complex structures, as in the NFPA, but also included other constructions, such as simple passives. This finding, together with a significant deficit in sentence repetition, suggests that a short-term phonological memory deficit could be the core mechanism underlying the clinical presentation of LPA." In 2008 the following features were required: (1) word retrieval deficits in spontaneous speech and confrontation naming, (2) impaired repetition of sentences, (3) errors in spontaneous speech and naming (eg, phonological errors), and (4) sparing of word and object knowledge and motor speech. The 2011 criteria require, both core features: (1) Impaired single-word retrieval in spontaneous speech and naming; (2) Impaired repetition of sentences and phrases; and at least 3 of the following features: (1) Speech (phonologic) errors in spontaneous speech and naming; (2) Spared single-word comprehension and object knowledge; and (3) Spared motor speech (4) Absence of frank agrammatism.
As shown above, all the features described in 2004 are also present in posterior versions of the criteria and the core deficits are the same for each variant. The main differences are additions of supporting features such as spared object knowledge in the non-fluent variant and surface dyslexia for the semantic variant. Another difference is the way in which some deficits are operationalized. For example, the deficit in word and object knowledge characteristic of the semantic variant was operationalized as impaired scores on the BNT and the PPT tests in 2004, whereas later publications did not specify particular tests, instead requiring impaired confrontation naming and semantic memory in 2008 and confrontation naming, single word comprehension, and object knowledge in 2011. The changes in the criteria have not changed the framework of the tripartite classification system, which is delineation of one variant with a predominant deficit in motor speech and grammar production, another variant with a predominant deficit in semantics, and another variant with a predominant deficit in word retrieval and phonologic processing. Therefore use of clinical judgment in the application of any of the versions of the criteria described above will result in identification of the same patients. In addition, classification was based on the same core clinical evaluation since 2002 further minimizing any potential effects produced by the changes in criteria.
